Tag Archives: gene

Bluebird CEO defends $1.8 million gene therapy price — ‘It’s really thinking about it differently’

Bluebird Bio CEO Nick Leschly on Friday defended the biotech company’s $ 1.8 million price tag for its new gene therapy to treat a rare genetic blood disorder. Bluebird’s therapy, Zynteglo, was approved in Europe earlier this month for patients with beta thalassemia who require regular blood transfusions to manage their disease and have no… Read More »

Novartis slaps $2M-plus pricetag on newly approved gene therapy Zolgensma—and cost watchdogs approve

Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer. The Swiss drugmaker will roll out the drug, a one-time treatment for pediatric patients less than 2 years of… Read More »

Commentary: Novartis CEO: Gene therapy offers hope of cures in a treatment, but US needs new pricing, payment model

We live in an incredible era of progress in human health. Advances in cell and gene therapies are beginning to yield powerful new treatments for some of the most devastating illnesses. With many of these new therapies we are no longer combating diseases over time, but potentially curing them in a single treatment. This is… Read More »